Abstract Aliskiren is a novel blood pressure-lowering agent acting as an oral direct renin inhibitor. We evaluated the effects of aliskiren on the fibrinolytic system in patients with coronary artery disease who were receiving angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II type 1 receptor blockers (ARBs). We studied 17 patients with coronary artery disease whose systolic blood pressure was more than 130 mmHg despite treatment with ACEIs or ARBs. Aliskiren (150 mg) was added to ACEIs or ARBs, and was continued for 6 weeks. Aliskiren significantly decreased systolic blood pressure (140 ± 6-128 ± 8 mmHg, P \ 0.001) and plasma renin activity (1.8 ± 2.3-0.6 ± 0.9 ng/ml/h, P \ 0.01) after 6 weeks. However, it did not affect plasminogen activator inhibitor-1 (28.8 ± 14.5-30.6 ± 13.6 ng/ml, P = 0.84), fibrinogen (305 ± 72 vs 301 ± 71 mg/dl, P = 0.33), or D-dimer (0.49 ± 0.24-0.51 ± 0.28 lg/ml, P = 0.70) levels. Our data suggested that patients receiving ACEIs or ARBs would not be expected to have any changes in biomarkers of the fibrinolytic system with additional pharmacologic inhibition of the reninangiotensin-aldosterone system.
Introduction
Activation of the renin-angiotensin-aldosterone system (RAAS) has been known to be associated with an increased risk of cardiovascular disease [1] [2] [3] . There are numerous mechanisms whereby interruption of RAAS by angiotensin-converting enzyme inhibitors (ACEIs) could reduce cardiovascular mortality. One possible mechanism is the interaction of the RAAS and fibrinolytic system leading to a procoagulatory status. ACEIs are recommended as standard therapy in patients with established cardiovascular disease [4] [5] [6] . Angiotensin II type 1 receptor blockers (ARBs) also inhibit RAAS in a mechanistically distinct fashion from ACEIs, and are widely used as the alternative agent because of their better tolerability [7, 8] . Aliskiren is a novel blood pressure-lowering agent acting as an oral direct renin inhibitor, and blocks the first and rate-limiting step in the RAAS; this complementary mechanism provides significant decreases in plasma renin activity (PRA), angiotensin I, angiotensin II, and aldosterone [9] . Although previous studies have assessed the effects of ACEIs or ARBs on the fibrinolytic system [10] [11] [12] [13] , it remains unclear how direct renin inhibitors affect the fibrinolytic system. In this study, we examined whether aliskiren affected PRA, blood pressure, or fibrinolytic parameters in patients with coronary artery disease who were receiving ACEIs or ARBs.
Patients and methods

Patients
We studied 17 patients with coronary artery disease whose systolic blood pressure was more than 130 mmHg despite treatment with ACEIs or ARBs. Coronary artery disease was defined as [75% stenosis in one or more vessels, or history of myocardial infarction or percutaneous coronary intervention. Diabetes was defined as fasting hyperglycemia and drug (insulin or oral hypoglycemic agents) or dietary treatment. Patients with severe hypertension, acute coronary syndrome, or serum creatinine [1.4 mg/dl were excluded.
Study protocol
Aliskiren (150 mg) was added to ACEIs or ARBs, and was continued for 6 weeks. Aliskiren was titrated to a systolic blood pressure of \130 mmHg [14] . All other drugs including ACEIs, ARBs, b-blockers, and aldosterone antagonists were unchanged during the study period. Blood samples were obtained in the morning between 08.00 and 11.00 h after one night of fasting. After 15 min of rest in the sitting or supine position, blood was drawn from an antecubital vein for measurement of PRA, plasma aldosterone concentration (PAC), plasminogen activator inhibitor-1 (PAI-1), fibrinogen, and D-dimer. Hemodynamic measurements and analysis of RAAS and fibrinolytic systems were performed before and 6 weeks after the treatment with aliskiren. Informed consent was obtained from all patients.
Analytical procedures
Blood for PRA and PAC was drawn into chilled tubes containing ethylenediamine tetraacetic acid. Plasma renin activity was measured by radioimmunoassay for angiotensin I formation at pH 7.4 and 37°C. Plasma aldosterone concentration was measured by commercially available radioimmunoassay. Plasma PAI-1 was measured by commercially available latex photometric immunoassay [15, 16] . In this assay, total PAI-1 was stable at 10-25°C for 5 days after separation of plasma. Fibrinogen was measured by the Claus method. D-dimer was measured by commercially available radioimmunoassay.
Statistical analysis
Continuous variables are presented as mean ± SD, and categorical variables are presented as percent frequencies. Statistical analysis was performed with the paired Student's t test for continuous variables. The chi-square test was used for categorical variables. Differences were considered significant if the P value was less than 0.05.
Results
Patients' characteristics
Patients' characteristics are shown in Table 1 . There were 6 male and 11 female patients with a mean age of 73 ± 12 years. Seven patients had prior myocardial infarction, and 14 patients had a history of percutaneous coronary intervention. Five patients were receiving ACEIs and the remaining 12 patients were receiving ARBs.
Effects of aliskiren on hemodynamics
The treatment with aliskiren significantly decreased systolic blood pressure (140 ± 6-128 ± 8 mmHg, P \ 0.001) ( Table 2 ). There was also a trend toward a decrease in diastolic blood pressure (73 ± 10-67 ± 8 mmHg, P = 0.07).
Effects of aliskiren on RAAS (Table 2) The treatment with aliskiren significantly decreased PRA (1.8 ± 2.3-0.6 ± 0.9 ng/ml/h, P \ 0.01, Fig. 1 ) and increased PAC to PRA ratio (18.2 ± 20.9-38.3 ± 33.6, P = 0.02), whereas it did not affect PAC (10.5 ± 5.4-9.8 ± 4.7 pg/ml, P = 0.22).
Effects of aliskiren on fibrinolytic system
Before the treatment with aliskiren, there was no significant difference in PAI-1 (28.0 ± 6.8 vs 29.1 ± 16.7 ng/ml, P = 0.86), fibrinogen (328 ± 23 vs 296 ± 84 mg/dl, P = 0.24), or D-dimer (0.62 ± 0.29 vs 0.43 ± 0.19 lg/ml, P = 0.23) ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II type 1 receptor blocker levels between patients receiving ACEIs and those receiving ARBs. Aliskiren did not affect PAI-1 (28.8 ± 14.5-30.6 ± 13.6 ng/ml, P = 0.84), fibrinogen (305 ± 72 vs 301 ± 71 mg/dl, P = 0.33), or D-dimer (0.49 ± 0.24-0.51 ± 0.28 lg/ml, P = 0.70) levels in patients receiving ACEIs or ARBs (Table 2) .
Discussion
This study demonstrated that aliskiren in addition to ACEIs or ARBs significantly decreased PRA as well as systolic blood pressure. However, it did not affect fibrinolytic parameters in patients with coronary artery disease. Previous studies demonstrated that ACEIs decreased plasma PAI-1 antigen, but provide conflicting evidence as to the effect of ARBs on the fibrinolytic system. Brown et al. studied the effects of ACEIs and ARBs for 6 weeks on PAI-1 antigen in hypertensive patients. They demonstrated that short-term interruption of the RAAS by either ACEIs or ARBs decreased PAI-1 antigen, but the effect of ARBs on PAI-1 antigen was not sustained throughout the 6-week period [12] . The observation that ARBs increase PAI-1 relative to ACEIs may point to an adverse effect of these agents on plaque vulnerability [17] . On the other hand, our patients were receiving ACEIs or ARBs for at least 3 months, and there was no significant difference in PAI-1 between patients receiving ACEIs and those receiving ARBs. The long-term use of ACEIs is associated with increased angiotensin I level, leading to increased production of angiotensin II via non-ACE pathways. Increased angiotensin II results in an activation of the angiotensin II type 1 receptor, which is responsible for the increased production of PAI-1 [18] . We assume that the similar level of PAI-1 is due to the activation of non-ACE mechanisms.
Previous studies have shown that pharmacologic manipulation of the RAAS with ACEIs or ARBs improves outcomes in cardiovascular disease. However, it provides only partial protection from disease progression. One possible mechanism is reactive increases in PRA and angiotensin I leading to increased production of angiotensin II via non-ACE pathways [18] . Another mechanism is the increased circulating PAC after initial suppression with ACEIs or ARBs; the so-called aldosterone breakthrough [19, 20] . This study showed that aliskiren buffered the ACEI-or ARB-induced increases in PRA, and decreased systolic blood pressure. These results were consistent with those of previous reports assessing aliskiren-based combination therapy [21, 22] . This study also showed that aliskiren did not affect PAC and fibrinolytic parameters. There has been no report assessing the effect of aliskiren on fibrinolytic system in vivo, but Serebruany et al. reported an in vitro effect in volunteers with multiple risk factors for vascular disease [23] . They showed that aliskiren in vitro increased antithrombin-III activity and did not affect fibrinogen or D-dimer in the therapeutic concentration, although tissue plasminogen activator and PAI-1 were not assessed. Their results could be contributed to the chemical compound itself rather than being explained by the immediate modulation of the RAAS. In our study in vivo, aliskiren did not affect fibrinolytic parameters despite decreased PRA. In our study, 7 patients were receiving b-blockers and 12 patients were receiving statins. b-Blockers decrease the activity of RAAS and the PAI-1 level in patients with hypertension or heart failure. Statins also have been shown to reduce oxidative stress and inhibit inflammation, and thus improve endothelial function resulting in a decreased PAI-1 level. We assume that the effects of these agents are partially responsible for the lack of attenuation of fibrinolytic parameters. Our results suggest that aggressive therapy with these agents is more effective in improving fibrinolytic parameters rather than additional pharmacologic inhibition of the RAAS in patients receiving ACEIs or ARBs. Further studies are necessary to clarify the effects of aliskiren on the fibrinolytic system in high-risk patients with more activated RAAS.
Study limitations
There were several limitations in this study. First, we assessed the effect of aliskiren for 6 weeks, but long-term follow-up data were not obtained. Second, we did not assess the effect of higher doses of aliskiren. There is a possibility that higher doses of aliskiren affect fibrinolytic parameters in patients with coronary artery disease. However, it was noteworthy that aliskiren significantly decreased PRA in this study. Third, we assessed the effect of aliskiren under optimal medical therapy for coronary artery disease, namely ACEIs, ARBs, b-blockers, or statins. These agents are known to be associated with a decrease in fibrinolytic parameters. Finally, the small sample size is a major limitation, and a larger study should be performed to confirm our findings.
Conclusion
Our data demonstrated that aliskiren for 6 weeks significantly decreased PRA as well as systolic blood pressure, but did not affect fibrinolytic parameters in patients with coronary artery disease receiving ACEIs or ARBs. Our study suggested that patients receiving ACEIs or ARBs would not be expected to have any changes in biomarkers of the fibrinolytic system with additional pharmacologic inhibition of the RAAS.
